Connective Tissue Growth Factor: Regulation, Diseases, and Drug Discovery

Int J Mol Sci. 2024 Apr 25;25(9):4692. doi: 10.3390/ijms25094692.

Abstract

In drug discovery, selecting targeted molecules is crucial as the target could directly affect drug efficacy and the treatment outcomes. As a member of the CCN family, CTGF (also known as CCN2) is an essential regulator in the progression of various diseases, including fibrosis, cancer, neurological disorders, and eye diseases. Understanding the regulatory mechanisms of CTGF in different diseases may contribute to the discovery of novel drug candidates. Summarizing the CTGF-targeting and -inhibitory drugs is also beneficial for the analysis of the efficacy, applications, and limitations of these drugs in different disease models. Therefore, we reviewed the CTGF structure, the regulatory mechanisms in various diseases, and drug development in order to provide more references for future drug discovery.

Keywords: CTGF-related diseases; CTGF/CCN2; drug discovery; regulation mechanism; therapeutic target.

Publication types

  • Review

MeSH terms

  • Animals
  • Connective Tissue Growth Factor* / metabolism
  • Drug Discovery* / methods
  • Eye Diseases / drug therapy
  • Eye Diseases / metabolism
  • Fibrosis
  • Gene Expression Regulation / drug effects
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Nervous System Diseases / drug therapy
  • Nervous System Diseases / metabolism

Substances

  • Connective Tissue Growth Factor